Revvity, Inc. Stock Price
- 3 Narratives written by author
- 0 Comments on narratives written by author
- 16 Fair Values set on narratives written by author
RVTY Community Narratives
RVTY: Operating Margins And Buyback Plan Will Drive Share Recovery Ahead
Regulatory Shifts Will Pressure Diagnostics Yet Spur Measured Turnaround
Genomics And Automation Will Expand Diagnostics In Aging Populations
Genomics And Automation Will Expand Diagnostics In Aging Populations
View narrativeRVTY: Operating Margins And Buyback Plan Will Drive Share Recovery Ahead
View narrativeRegulatory Shifts Will Pressure Diagnostics Yet Spur Measured Turnaround
View narrativeTrending Discussion
No trending discussion available.
Recently Updated Narratives
RVTY: AI Screening Demand And Sector Recovery Will Support Future Upside
RVTY: Elevated Multiple And Sector Headwinds Will Challenge 2026 Outlook
RVTY: AI R&D Tools And Sector Backdrop Will Shape Future Earnings Power
Snowflake Analysis
Revvity, Inc. Key Details
About RVTY
- Founded
- 1937
- Employees
- 11000
- CEO
- Website
View website
Revvity, Inc. provides health sciences solutions, technologies, and services. The company offers instruments, reagents, software, subscriptions, detection and imaging technologies, extended warranties, training and services; and instruments, reagents, assay platforms and software products for early detection of common and rare conditions, such as pregnancy and early childhood, as well as infectious disease testing in the diagnostics market. Its products are used for testing and screening genetic abnormalities, disorders, and diseases, including down syndrome, hypothyroidism, muscular dystrophy, infertility, and various metabolic conditions. The company also develops technologies that enable and support genomic workflows using protein coupled receptor and next-generation DNA sequencing for oncology, immunodiagnostics, and drug discovery. It serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies under the AutoDELFIA, chemagic, Chitas, CNGnome, DELFIA, DELFIA Xpress, EONIS, EUROArray , EUROIMMUN, EUROLabWorkstation, EUROLINE, EUROPattern, Evolution Evoya, GSP, Haoyuan, IDS Immunodiagnosticsystems, IDS-i10, IDS-i10T, IDS-i20, IDS-iSYS, iLab, iQ, LifeCycle, LimsLink, Migele, NeoBase, NeoLSD, NEXTFLEX, Panthera Puncher, PreNAT II, Prime, RONIA, SimplicityChrom, Specimen Gate, Superflex, Symbio, T-SPOT, Vanadis, ViaCord, VICTOR2, and WholePanel brand names, as well as under the Accell, AlphaLISA, AlphaPlex, AlphaScreen, Alpha SureFire, AssayMate, BIOCHIPs, BioLegend, Bioo Scientific, BioQule, Brilliant Violet, Ce3D, CellCarrier, Cellaca, Celigo, Cellometer, cell::explorer, Cell-Vive, Chalice, ChemDraw, CHOSOURCE, Dharmacon, and DharmaFECT brand names. The company was formerly known as PerkinElmer, Inc. and changed its name to Revvity, Inc. in April 2023. Revvity, Inc. was founded in 1937 and is headquartered in Waltham, Massachusetts.